ValitaCell Ltd. (“ValitaCell”), has been sold to Beckman Coulter Life Sciences, part of the Danaher Corporation (NYSE: DHR). Headquartered in Dublin, Ireland, ValitaCell creates analytical technologies and products for the biopharmaceutical industry with the goal of reducing new therapeutics’ cost and time to market.

ValitaCell develops critical reagent and software solutions enabling biopharmaceutical companies to bring medicines to the market faster, cheaper, and with greater regulatory confidence. ValitaCell’s three technology platforms include: (i) Quantum (reagent platform enabling measurement of Key Process Parameters and CQAs during biomanufacturing); (ii) ChemStress (plate-based, microscale simulation platform to improve process analytics); and (iii) CellAi (AI-powered image analysis software).

Beckman Coulter Life Sciences (“BCLS”) develops tools to help optimise life sciences research and manufacturing efficiency, including particle counters/analysers, automated liquid handlers, flow cytometers, and genomic reagents, among many more. BCLS’ technologies serve a range of customers from universities and major pharmaceutical companies, to small biotech start-ups, food/beverage, and electronics manufacturing facilities.

Danaher, based in the USA, is a NYSE-listed global science and technology company that designs, manufactures and markets a broad range of innovative products and services with premier brand names and leading market positions worldwide. Danaher generates revenues of approximately $29 billion and has a market capitalisation of approximately $175 billion. Danaher Life Sciences Platform includes instrument brands such as Beckman Coulter, Leica, SCIEX, Biacore, and Molecular Devices, as well as brands throughout the biopharma, bioprocessing, and genomics workflow like Cytiva, Pall, IDT, and Aldevron.

Terms of the transaction were not disclosed.

EC M&A acted as exclusive financial advisor to ValitaCell on this transaction.